TABLE 2.
Comparative in vivo activities of DW-224a against systemic infections in mice
| Microorganism inoculum (CFU/mouse) | Mucin (%) | Antimicrobial agenta | MIC (μg/ml) | ED50 (mg/kg) (95% confidence limits) |
|---|---|---|---|---|
| S. aureus giorgio (1 × 108) | 5 | DW-224a | <0.008 | 1.11 (0.17-4.64) |
| Ciprofloxacin | 0.125 | 16.52 (1.27-18.99) | ||
| Moxifloxacin | 0.03 | 1.78 (0.33-7.66) | ||
| Gemifloxacin | <0.008 | 1.37 (0.27-7.67) | ||
| MRSA P197 (5 × 109) | 5 | DW-224a | 0.25 | 15.52 (9.02-26.58) |
| Ciprofloxacin | 8 | >40 | ||
| Moxifloxacin | 1 | 35.35 (20.38-61.33) | ||
| Gemifloxacin | 0.25 | 26.58 (15.03-47.28) | ||
| S. pneumoniae ATCC 6305 (1 × 104)b | DW-224a | 0.008 | 0.53 (0.0029-1.67) | |
| Ciprofloxacin | 0.5 | 10.46 (3.56-32.26) | ||
| Moxifloxacin | 0.06 | 2.00 (0.41-6.21) | ||
| Gemifloxacin | 0.015 | 0.76 (0.15-2.43) | ||
| S. pyogenes B144 (5 × 107) | 5 | DW-224a | 0.06 | 2.65 (0.65-13.73) |
| Ciprofloxacin | 4 | >40 | ||
| Moxifloxacin | 0.25 | 9.04 (2.16-73.6) | ||
| Gemifloxacin | 0.06 | 2.83 (0.37-15.24) | ||
| E. coli 851E (1 × 108) | 5 | DW-224a | 0.03 | 6.08 (1.64-38.80) |
| Ciprofloxacin | 0.008 | 0.78 (0.10-3.20) | ||
| Moxifloxacin | 0.06 | 2.17 (0.61-7.73) | ||
| Gemifloxacin | 0.015 | 1.16 (0.25-4.13) | ||
| K. pneumoniae P427 (5 × 105) | 5 | DW-224a | 0.06 | 9.77 (2.77-36.20) |
| Ciprofloxacin | 0.06 | 0.70 (0.00-2.59) | ||
| Moxifloxacin | 0.25 | 2.64 (0.36-10.68) | ||
| Gemifloxacin | 0.03 | 5.36 (1.42-20.20) | ||
| M. morganii 1375E (2 × 106) | 5 | DW-224a | 0.125 | 4.83 (0.49-26.77) |
| Ciprofloxacin | 0.008 | 1.41 (0.17-5.91) | ||
| Moxifloxacin | 0.125 | 5.28 (1.50-18.45) | ||
| Gemifloxacin | 0.06 | 3.41 (0.77-12.48) |
a
Antimicrobial agents were orally administered at 1 and 4 h after infection.
b
Bacterial strains were suspended in 0.9% saline solution containing 5% gastric mucin, except for S. pneumoniae ATCC 6305, which was suspended in 0.9% saline solution.